Novel Alternative Drugs for Hospital-acquired Methicillin-Resistant Staphylococcus aureus Infection
Article Sidebar
Main Article Content
Abstract
Nowadays, MRSA is a common cause of nosocomial infection and is often associated with invasive infections and high rates of mortality. Vancomycin has remained the mainstay of therapy for serious gram-positive infections including MRSA. However, therapeutic failures with vancomycin have been increasingly reported from many studies. Hence, it has been associated with suboptimal outcomes. New agents for the treatment of MRSA are required. Novel alternative drugs for MRSA infection such as linezolid, daptomycin and tigecycline which available in Thailand have been substituted with vancomycin. These new medications will be considered for patient with failure or unsatisfied response from vancomycin treatment owing to VISA or VRSA infection. The purpose of this review is to discuss the incidence of MRSA in Thailand, treatment failure of vancomycin and alternative treatment for MRSA infection from several clinical studies. This information will be useful for physicians, pharmacists and healthcare personals for considering the appropriate treatment of MRSA in order to maximize efficacy and decrease resistance rate especially VISA and VRSA.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Anthony KB, Fishman NO, Linkin DR, et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567–70.
Appelbaum PC. Reduced glycopeptide susceptibility in Methicillin-resistant Staphylococcus
aureus (MRSA). Int J Antimicrob Agents 2007; 30: 398-408.
Babinchak T, Ellis-Grosse E, Dartois N, et al. The effi cacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41: 354–67.
Bennett JW, Murray CK, Holmes RL, et al. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with Methicillinresistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2008; 60: 437-40.
Breedt J, Teras J, Gardovkis J, et al. Safety and effi cacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658–66.
Cai Y, Wang R, Liang B, et al. Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease. Antimicrob Agents Chemother 2011; 55: 1162-72.
Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram positive pathogens. Clin Infect Dis 2004; 38: 994-1000.
Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of gram positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 17-24.
Chuamuangphan T, Chongtrakool P, Sungkanuparph S. Predicting Factors of Methicillin-resistant Staphylococcus aureus Bacteremia among Hospitalized Patients in a Tertiary-care Hospital: A Case-control Study. J Infect Dis Antimicrob Agents 2014; 31: 79-89.
Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial SusceptibilityTesting. Wayne:CLSI; 2006. 16th Informational Supplement, M100-S16.
Conte Jr. JE, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25: 523-9.
Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of Mortality Associated with Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Meta-analysis. Clin Infect
Dis 2003; 36: 53–9.
Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011; 66: 7–15.
FDA Drug Safety Communication. Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm. Accessed date September 2, 2015.
Florescu I, Beuran M, Dimov R, et al. Effi cacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62: 17-28.
Fowler VG, Boucher HW, Corey R, et al. Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
Hidayat LK, Hsu DI, Quist R, et al. High dose vancomycin therapy for Methicillin-resistant Staphylococcus aureus infections: effi cacy and toxicity. Arch Intern Med 2006; 166:2138–44.
Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance
mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23(1): 99-139.
Hung WY, Kogelman L, Volpe G, et al. Tigecyclineinduced acute pancreatitis: case report and literature review. Int J Antimicrob Agents 2009; 34(5): 486-9.
Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for Methicillin-resistant Staphylococcus aureus health- care-associated pneumonia: specifi c evaluation of vancomycin pharmacokinetic indices.
Chest 2006; 130: 947-55.
Jeu L, Fung HB. Daptomycin: a cycliclipopeptide antimicrobial agent. Clin Ther 2004; 26:1728-57.
Kalil AC, Klompas M, Haynatzki G, et al. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 2013; 3: 1-10.
Lentino JR, Narita M, Yu YL. New antimicrobial agents as therapy for resistant grampositive cocci. Eur J Clin Microbiol Infect Dis 2008; 27: 3-15.
Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clin Infect Dis 2011; 51:1-38.
Lodise TP, Graves J, Evans A, et al. Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin. Antimicrob Agents Chemother 2008; 52:3315-20.
Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-6.
McDaneld PM, Spooner LM, Mohr JF, et al. Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 ug/mL. Ann Pharmacother 2013; 47: 1654-65.
Meagher AK, Ambrose PG, Grasela TH. The Pharmacokinetic and Pharmacodynamic Profi le of Tigecycline. Clin Infect Dis 2005; 41: 333-40.
Moore CL, Lu M, Cheema F, et al. Prediction of Failure in Vancomycin-Treated Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: a Clinically Useful Risk Stratifi cation Tool. Antimicrobial Agents Chemother 2011; 55: 4581-8.
Moore CL, Osaki-Kiyan P, Haque NZ, et al. Daptomycin versus vancomycin for bloodstream infections due to methicillinresistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012; 54: 51-8.
Murray KP, Zhao J, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin MIC>1 mg/L: a matched cohort study. Clin Infect Dis 2013; 56: 1562-9.
National Antimicrobial Resistance Surveillance Center of Thailand (NARST). Available at http://narst.dmsc.moph.go.thantibiograms/12m/Jan-Dec2014-All.pdf. Accessed date September 2, 2015.
Parsonage M, Shah S, Moss P, et al. Breakthrough bacteraemia with a susceptible Enterococcus faecalis during tigecycline monotherapy. J Antimicrob Chemother 2010; 65; 370-4.
Pertel PE, Bernardo P, Fogarty C, et al. Effects of Prior Effective Therapy on the Effi cacy of Daptomycin and Ceftriaxone for the Treatment of Community-Acquired Pneumonia. Clin Infect Dis 2008; 46: 1142–51.
Ramirez J, Dartois N, Gandjini H, et al. Randomized Phase 2 Trial To Evaluate the Clinical Effi cacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia. Antimicrob Agents Chemother 2013; 57(4): 1756-62.
Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases
Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 2009; 66: 82-98.
Safdar N, Andes D, Craig WA. In vivo pharmacodynamics activity of daptomycin. Antimicrob Agents Chemother 2004; 48: 63-8.
Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to effi cacy of vancomycin for treatment of methicillin-resistant Staphylococcusaureus bacteremia. J Clin Microbiol 2004; 42: 2398–402.
Song JH, Hsueh PR, Chung DR, et al. Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother 2011; 66: 1061-9.
Stevens DL, Herr D, Lampiris H, et al. versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-90.
Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43: 180-7.
Tenover FC. Mechanism of antimicrobial resistance in bacteria. Am J Med 2006; 119: 3-10.
Tishyadhigama P, Dejsirilert S, Thongmali O. Antimicrobial Resistance among Clinical Isolates of Staphylococcus aureus in Thailand from 2000 to 2005. J Med Assoc Thai 2009; 92: 8-18.
Trakulsomboon S, Thamlikitkul V. In Vitro activity of Tigecycline against methicillin-resistant Staphylococcus aureus isolated from the patients at Siriraj hospital. J Infect Dis Antimicrob Agents 2006; 23: 1-4.
See comment in PubMed Commons below Vilhena C, Bettencourt A. Daptomycin: a review of properties, clinical use, drug delivery and resistance. Mini Rev Med Chem 2012; 12: 202-9.
Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study. Clin Infect Dis 2012; 54: 621-9.
Wysocki M, Delatour F, Faurisson F, et al. Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized Study. Antimicrob Agent Chemother 2001; 45(9): 2460-7.
Yahav D, Lador A, Paul M, et al. Effi cacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66(9): 1963-71.